TransMedics raised full-year revenue guidance to $764 million to $774 million after its biggest quarter ever, before PAD Aviation contributes anything. Liver and heart volume through the National OCS Program is still compounding, and ENHANCE Heart Part B, DENOVO Lung and an OCS Kidney human study are all queued for 2027.
Latest Activity
TMDX Coverage
Live Earnings: Will TransMedics (TMDX) Rally After Earnings?
Live Updates Final take on tonight's earnings 5:26pm ETPost-Earnings Move: 🟢 +6.48% What Happened:Revenue of $157.4M beat by ~7% and EPS of $0.92 more than doubled the $0.43 consensus. Net income jumped…
5 Growth Stocks Poised to Grow Faster than NVIDIA Next Year
In 2024, the fastest-growing stocks have been in the momentum category, led by NVIDIA (NASDAQ: NVDA) | NVDA Price Prediction. We reviewed the sales growth rates of some of the other fastest-growing…